- Home
- DTST vs MURA Comparison
DTST vs MURA Comparison
Compare DTST & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- MURA
- Stock Information
- Founded
- DTST 2001
- MURA 2013
- Country
- DTST United States
- MURA Ireland
- Employees
- DTST N/A
- MURA N/A
- Industry
- DTST EDP Services
- MURA
- Sector
- DTST Technology
- MURA
- Exchange
- DTST Nasdaq
- MURA Nasdaq
- Market Cap
- DTST 32.6M
- MURA 35.7M
- IPO Year
- DTST N/A
- MURA N/A
- Fundamental
- Price
- DTST $4.61
- MURA $2.08
- Analyst Decision
- DTST
- MURA Strong Buy
- Analyst Count
- DTST 0
- MURA 3
- Target Price
- DTST N/A
- MURA $12.00
- AVG Volume (30 Days)
- DTST 75.9K
- MURA 467.6K
- Earning Date
- DTST 11-13-2025
- MURA 11-12-2025
- Dividend Yield
- DTST N/A
- MURA N/A
- EPS Growth
- DTST N/A
- MURA N/A
- EPS
- DTST N/A
- MURA N/A
- Revenue
- DTST $25,455,742.00
- MURA N/A
- Revenue This Year
- DTST $12.57
- MURA N/A
- Revenue Next Year
- DTST $9.29
- MURA N/A
- P/E Ratio
- DTST N/A
- MURA N/A
- Revenue Growth
- DTST 0.53
- MURA N/A
- 52 Week Low
- DTST $2.93
- MURA $0.95
- 52 Week High
- DTST $5.44
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- DTST 53.94
- MURA 52.67
- Support Level
- DTST $4.42
- MURA $2.05
- Resistance Level
- DTST $4.70
- MURA $2.09
- Average True Range (ATR)
- DTST 0.11
- MURA 0.01
- MACD
- DTST -0.01
- MURA 0.02
- Stochastic Oscillator
- DTST 64.41
- MURA 75.00
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.